Racura Oncology
ASX: RACSydney, Australia· Est.
Racura Oncology leverages G‑quadruplex‑binding small molecules to silence MYC and deliver cardioprotective cancer therapy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Racura Oncology leverages G‑quadruplex‑binding small molecules to silence MYC and deliver cardioprotective cancer therapy.
Oncology
Technology Platform
Small‑molecule G‑quadruplex DNA/RNA binder that silences MYC transcription, delivering anti‑tumor activity and cardioprotection.
Opportunities
Licensing or partnership deals for RC220 across multiple oncology indications and cardioprotective indications could accelerate global reach and unlock significant revenue streams.
Risk Factors
Clinical trial failures, regulatory delays, and competition from other MYC‑targeted or G4‑binding agents could impede progress and affect valuation.
Competitive Landscape
Racura competes with other MYC inhibitors and G4‑targeting molecules, but its dual anti‑tumor and cardioprotective profile offers a distinctive therapeutic advantage.